A metabolic biosignature of early response to anti-tuberculosis treatment

BACKGROUND: The successful treatment of tuberculosis (TB) requires long-term multidrug chemotherapy. Clinical trials to evaluate new drugs and regimens for TB treatment are protracted due to the slow clearance of Mycobacterium tuberculosis (Mtb) infection and the lack of early biomarkers to predict...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahapatra, Sebabrata, Hess, Ann M, Johnson, John L, Eisenach, Kathleen D, DeGroote, Mary A, Gitta, Phineas, Joloba, Moses L, Kaplan, Gilla, Walzl, Gerhard, Boom, W Henry, Belisle, John T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3918231/
https://www.ncbi.nlm.nih.gov/pubmed/24484441
http://dx.doi.org/10.1186/1471-2334-14-53

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3918231/
https://www.ncbi.nlm.nih.gov/pubmed/24484441
http://dx.doi.org/10.1186/1471-2334-14-53

Ejemplares similares